Abstract
Introduction Addiction consult services (ACS) engage hospitalized patients with opioid use disorder (OUD) in care and help meet their goals for substance use treatment. Little is known about how ACS affect mortality for patients with OUD. The objective of this study was to design and validate a model that estimates the impact of ACS care on 12-month mortality among hospitalized patients with OUD.
Methods We developed a Markov model of referral to an ACS, post-discharge engagement in SUD care, and 12-month drug-related and non-drug related mortality among hospitalized patients with OUD. We populated our model using Oregon Medicaid data and validated it using international modeling standards.
Results There were 6,654 patients with OUD hospitalized from April 2015 through December 2017. There were 114 (1.7%) drug-related deaths and 408 (6.1%) non-drug related deaths at 12 months. Bayesian logistic regression models estimated four percent (4%, 95% CI= 2%, 6%) of patients were referred to an ACS. Of those, 47% (95% CI= 37%, 57%) engaged in post-discharge OUD care, versus 20% not referred to an ACS (95% CI= 16%, 24%). The risk of drug-related death at 12 months among patients in post-discharge OUD care was 3% (95% CI= 0%, 7%) versus 6% not in care (95% CI = 2%, 10%). The risk of non-drug related death was 7% (95% CI =1%, 13%) among patients in post-discharge OUD treatment, versus 9% not in care (95% CI= 5%, 13%).
Discussion Our novel Markov model reflects trajectories of care and survival for patients hospitalized with OUD. This model can be used to evaluate the impact of other clinical and policy changes to improve patient survival.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported through grants from the National Institutes of Health, National Institute on Drug Abuse (UG1DA015815, UG3DA044831). Grant UL1TR002369 provided support of REDCap, the web application this study used for data collection. Caroline King was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Award Number TL1TR002371. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Oregon Health & Science University's Institutional Review Board approved this study (#00010846).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵1 Financial support for this study was provided in part by the following grants: UG1DA015815 (NIDA), UG3DA044831 (NIDA), UL1TR002369 (NCRR), TL1TR002371 (NCATS). The funding agreement ensured the authors’ independence in designing the study, interpreting the data, writing, and publishing the report.
Data Availability
Data may be available pending appropriate data access permissions and approval through OHSU's IRB.
